ARVN · Insider Trading
Arvinas, Inc
Every open-market purchase and sale reported by ARVN officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-06-26 | Linda Bain | Director | A | +15,527 | — |
| 2026-06-26 | Leslie V Norwalk | Director | A | +15,527 | — |
| 2026-06-26 | Everett Cunningham | Director | A | +15,527 | — |
| 2026-06-26 | Edward Moore Kennedy Jr. | Director | A | +15,527 | — |
| 2026-06-26 | Alsup Laurie Smaldone | Director | A | +15,527 | — |
| 2026-06-26 | Briggs Morrison | Director | A | +15,527 | — |
| 2026-06-24 | Andrew Saik | Chief Financial Officer | Sell | −5,696 | −$46.47K |
| 2026-06-18 | Angela M Cacace | Chief Scientific Officer | Sell | −2,576 | −$19.56K |
| 2026-05-22 | Randy Teel | President and CEO | Sell | −2,209 | −$19.96K |
| 2026-05-13 | Randy Teel | President and CEO | Sell | −9,657 | −$95.97K |
| 2026-05-13 | David K Loomis | VP, Chief Accounting Officer | Sell | −1,919 | −$19.07K |
| 2026-05-13 | Noah Berkowitz | Chief Medical Officer | Sell | −11,108 | −$110.38K |
| 2026-05-13 | Angela M Cacace | Chief Scientific Officer | Sell | −9,657 | −$95.97K |
| 2026-05-13 | Andrew Saik | Chief Financial Officer | Sell | −11,139 | −$110.69K |
| 2026-03-19 | Noah Berkowitz | Chief Medical Officer | Sell | −6,435 | −$71.43K |
| 2026-03-12 | Randy Teel | President and CEO | A | +147,179 | — |
| 2026-03-09 | Briggs Morrison | Director | Buy | +20,000 | +$268.07K |
| 2026-03-02 | Randy Teel | President and CEO | A | +147,791 | — |
| 2026-03-02 | Angela M Cacace | Chief Scientific Officer | A | +45,000 | — |
| 2026-03-02 | Noah Berkowitz | Chief Medical Officer | A | +45,000 | — |
| 2026-03-02 | Andrew Saik | Chief Financial Officer | A | +45,000 | — |
| 2026-03-02 | John G Houston | Director | Sell | −35,297 | −$466.15K |
| 2026-03-02 | David K Loomis | VP, Chief Accounting Officer | A | +12,420 | — |
| 2026-02-25 | David K Loomis | Chief Accounting Officer | Sell | −1,108 | −$13.47K |
| 2026-02-25 | Randy Teel | President and CEO | Sell | −4,786 | −$58.20K |
| 2026-02-25 | Angela M Cacace | Chief Scientific Officer | Sell | −3,609 | −$43.89K |
| 2026-02-18 | Andrew Saik | Chief Financial Officer | Sell | −5,134 | −$61.04K |
| 2026-02-18 | Noah Berkowitz | Chief Medical Officer | Sell | −5,685 | −$67.59K |
| 2026-02-18 | David K Loomis | Chief Accounting Officer | Sell | −1,016 | −$12.08K |
| 2026-02-18 | Randy Teel | President and CEO | Sell | −4,403 | −$52.35K |
| 2026-02-18 | Angela M Cacace | Chief Scientific Officer | Sell | −4,592 | −$54.60K |
| 2025-11-07 | David K Loomis | Chief Accounting Officer | Sell | −230 | −$2.27K |
| 2025-09-24 | Briggs Morrison | Director | Buy | +30,000 | +$227.01K |
| 2025-06-30 | Sunil Agarwal | Director | A | +16,025 | — |
| 2025-06-27 | Linda Bain | Director | A | +16,025 | — |
| 2025-06-27 | Alsup Laurie Smaldone | Director | A | +16,025 | — |
| 2025-06-27 | John D Young | Director | A | +16,025 | — |
| 2025-06-27 | Briggs Morrison | Director | A | +16,025 | — |
| 2025-06-27 | Leslie V Norwalk | Director | A | +16,025 | — |
| 2025-06-27 | Everett Cunningham | Director | A | +16,025 | — |
| 2025-06-27 | Edward Moore Kennedy Jr. | Director | A | +16,025 | — |
| 2025-06-24 | Andrew Saik | Chief Financial Officer | Sell | −5,700 | −$43.38K |
| 2025-06-18 | Angela M Cacace | Chief Scientific Officer | Sell | −2,583 | −$19.35K |
| 2025-05-13 | Angela M Cacace | Chief Scientific Officer | A | +59,600 | — |
| 2025-05-13 | David K Loomis | Chief Accounting Officer | A | +11,825 | — |
| 2025-05-13 | Andrew Saik | Chief Financial Officer | A | +59,600 | — |
| 2025-05-13 | Noah Berkowitz | Chief Medical Officer | A | +59,600 | — |
| 2025-03-19 | Noah Berkowitz | Chief Medical Officer | Sell | −8,658 | −$74.37K |
| 2025-02-25 | David K Loomis | Chief Accounting Officer | Sell | −1,214 | −$20.33K |
| 2025-02-25 | Angela M Cacace | Chief Scientific Officer | Sell | −4,207 | −$70.24K |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| John G Houston | President and CEO | 1,152,792 | $8.67M |
| Randy Teel | President and CEO | 285,009 | $2.14M |
| Noah Berkowitz | Chief Medical Officer | 191,395 | $1.44M |
| Andrew Saik | Chief Financial Officer | 187,432 | $1.41M |
| Angela M Cacace | Chief Scientific Officer | 180,390 | $1.36M |
| Ian Taylor | President, R&D | 160,785 | $1.21M |
| Briggs Morrison | Director | 111,548 | $838.84K |
| Edward Moore Kennedy Jr. | Director | 84,290 | $633.86K |
| Leslie V Norwalk | Director | 41,572 | $312.62K |
| Everett Cunningham | Director | 41,572 | $312.62K |
| Linda Bain | Director | 41,572 | $312.62K |
| Alsup Laurie Smaldone | Director | 41,572 | $312.62K |
| David K Loomis | VP, Chief Accounting Officer | 40,193 | $302.25K |
| Sunil Agarwal | Director | 30,166 | $226.85K |
| John D Young | Director | 26,045 | $195.86K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the ARVN quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.